Drug intelligence / Profile preview

VNRX-5024

Development stage: Phase 1
Lead developer: Venatorx Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

VNRX-5024 is a β-lactamase inhibitor under development by Venatorx Pharmaceuticals for the treatment of bacterial infections. It is being evaluated as an orally bioavailable agent designed to inhibit serine β-lactamases, including Ambler class A extended-spectrum β-lactamases (ESBLs), class C cephalosporinases, and class A and D carbapenemases such as KPC and OXA-48. The drug aims to restore the efficacy of oral β-lactam antibiotics against multidrug-resistant Enterobacterales that produce these enzymes. As of now, VNRX-5024 is in Phase 1 clinical trials assessing its safety and pharmacokinetics in healthy volunteers[1][2][3].

Targets

OXA (Class D beta-lactamase)AmpC (AmpC beta-lactamase)Class A BL (Class A beta-lactamase)

Beyond the preview

Go deeper on VNRX-5024.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VNRX-5024.

Explore the full profile